Search
Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)
CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.
Read moreCorporate Sponsor Program
View the EHA Ranking 2025
"Alone we can do so little; together we can do so much.
Lighting the Flame - Official launch
The European Hematology Association has now officially launched a new program, Lighting the Flame.
Read moreMessage from the EHA President
As the year closes, is with great pleasure that I reflect on 2021, six months into my Presidency of the European Hematology Association (EHA). It is also time to look forward to the new year.
Read moreMessage from the EHA Board
After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.
Read moreStreamlining SoHO Management in EU Hospitals
The European Commission's Directorate-General for Health and Food Safety (DG SANTE) is committed to improving the management of Substances of Human Origin (SoHO) in EU hospitals.
Read moreExpert opinions for specific non-malignant hematologic diseases
Red Cells and Iron
Hemoglobinopathies: Sickle Cell Disease and Thalassemia
Sickle Cell Disease Association of America (SCDSS)
Sickle Cell Disease and COVID-19: An Outline to Decrease Burden and Minimize Morbidity
Italian Society of Thalassemia and Hemoglobinopathies
Thalassemia and Hemoglobin disorders Italian Society
Thalassemia International Federation (TIF)
The COVID-19…
National Societies and EHA join forces for Ukraine
The European Hematology Association (EHA) and the European National Societies for Hematology want to express again, and publicly, their profound solidarity with the Ukrainian Hematology Society, and with Ukrainian hematology patients and their families.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- »